MarkTBergmannMDCataract Fellowship

Ophthalmology • Cincinnati, OH

Cataract Related, Cornea & External Disease, Refractive Surgery

Cataract Specialist/ Cornea & External Disease Specialist/ Comprehensive Ophthalmologist- Apex Eye

Join to view full profile

Dr. Bergmann is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Bergmann's full profile

Already have an account?

Office
6507 Harrison Avenue
Suite E
Cincinnati, OH 45247
Phone+1 513-661-3566

Fax+1 513-661-6469

Clinical Expertise

Dry eye, Cataracts, Diabetes, Laser general surgery, Clinical research, Glaucoma, No stitch, No patch, No shot cataract implant surgery. External eye disease, Diabetic eye exams, Eye research studies, Office lid lesion removal, Laser surgery-glaucoma & after cataract

Education & Training

Detroit Medical Center/Wayne State UniversityFellowship, Cornea, External Diseases, and Refractive Surgery, 1987 - 1987
Cullen Eye Institute-BaylorFellowship, Cataract Fellowship, 1986 - 1986
University of ToledoResidency, Ophthalmology, 1983 - 1986
Jewish Hospital of CincinnatiInternship, Internal Medicine, 1982 - 1983
Wright State University Boonshoft School of MedicineClass of 1982

Certifications & Licensure

OH State Medical License 1983 - 2025
American Board of Ophthalmology Ophthalmology

Awards, Honors, & Recognition

Top Doctor Cincinnati Magazine, 2013, 2017, 2021
CMS Meaningful Use Stage 1 Certification NextGen Ambulatory EHR, NextGen Healthcare, 2013
Fellow (FAAO) American Academy of Ophthalmology

Clinical Trials

Safety and Efficacy of KPI-121 in Subjects With Postsurgical Inflammation and Pain Start of enrollment: 2016 Jun 01
Completed
Phase 3

Publications & Presentations

PubMed

4 citations
Phase 3 Efficacy (Worse-Eye Analysis) and Long-Term Safety Evaluation of OTX-101 in Patients with Keratoconjunctivitis Sicca.
John D. Sheppard, M.T. Bergmann, Barry A. Schechter, Jodi Luchs, Abayomi Ogundele
Clinical Ophthalmology. 2021-01-12
4 citations
Pooled analysis of two studies evaluating efficacy and safety of olopatadine hydrochloride 0.77% in patients with allergic conjunctivitis
Eugene B McLaurin, M.T. Bergmann, Abhijit Narvekar, Adeniyi Adewale, Paul J Gomes
Clinical Ophthalmology. 2017-06-08
18 citations
Efficacy and safety of olopatadine hydrochloride 0.77% in patients with allergic conjunctivitis using a conjunctival allergen-challenge model.
Gail Torkildsen, Abhijit Narvekar, M.T. Bergmann
Clinical Ophthalmology. 2015-09-14

Research History

Principal InvestigatorPrincipal Investigator for several eye drop studies related to allergy, cataract surgery, dry eyes, conjunctivitis, and glaucoma.2007 - 2017

Professional Memberships

American Academy of Ophthalmology - AAO
Fellow

External Links

Cincinnati Eye Institute http://Cincinnatieye.com